SITE015-0227

SITE015 (POL) › SITE015-0227

SITE015-0227

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-05-30

enrolled

AEs

8

Serious

1

Dropout signal

–

Adverse events

8

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 102); relationship: NOT RELATED

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 99); relationship: NOT RELATED

moderate assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 86); relationship: NOT RELATED; serious criteria: hospitalization

severe serious under_review

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 83); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: UNKNOWN; onset 2023-02-03 (study day 64); relationship: NOT RELATED

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 47); relationship: not assessed

moderate assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-16 (study day 46); relationship: NOT RELATED

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 27); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.